British Biosimilars Association (BBA) launches in UK

(London – Monday, April 18th) A new industry body, the British Biosimilars Association (BBA), has been formally launched today with the sole focus of increasing the understanding and use of biosimilar medicines in the UK.

The BBA is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilar medicines. BBA members’ core focus will be ensuring patients can benefit from these lifesaving and life changing medicines to the same extent as those elsewhere in Europe. Currently, the UK lags behind some European countries in the take-up of biosimilar medicines. Restricting patient access to these medicines costs the NHS money that could be used for other treatments.